Celmatix Company

Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Celmatix's lead program aims to protect the ovary from chemotherapy-induced ovarian failure (CIOF). For the 1.9 million pre-menopausal women diagnosed with cancer, the need is critical, urgent, and unmet.
Technology: Longevity FemTech
Industry: Longevity
Headquarters: New York, New York, United States
Founded Date: 2009-01-01
Employees Number: 101-250
Funding Status: Early Stage Venture
Investors Number: 4
Total Funding: $53 660 000
Estimated Revenue: $10M to $50M
Last Funding Date: 2019-04-01
Last Funding Type: Venture - Series Unknown

Visit Website
http://twitter.com/celmatix
Register and Claim Ownership